首页> 美国卫生研究院文献>Experimental Biology and Medicine >Next generation human skin constructs as advanced tools for drug development
【2h】

Next generation human skin constructs as advanced tools for drug development

机译:下一代人类皮肤构造可作为药物开发的高级工具

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Many diseases, as well as side effects of drugs, manifest themselves through skin symptoms. Skin is a complex tissue that hosts various specialized cell types and performs many roles including physical barrier, immune and sensory functions. Therefore, modeling skin in vitro presents technical challenges for tissue engineering. Since the first attempts at engineering human epidermis in 1970s, there has been a growing interest in generating full-thickness skin constructs mimicking physiological functions by incorporating various skin components, such as vasculature and melanocytes for pigmentation. Development of biomimetic in vitro human skin models with these physiological functions provides a new tool for drug discovery, disease modeling, regenerative medicine and basic research for skin biology. This goal, however, has long been delayed by the limited availability of different cell types, the challenges in establishing co-culture conditions, and the ability to recapitulate the 3D anatomy of the skin. Recent breakthroughs in induced pluripotent stem cell (iPSC) technology and microfabrication techniques such as 3D-printing have allowed for building more reliable and complex in vitro skin models for pharmaceutical screening. In this review, we focus on the current developments and prevailing challenges in generating skin constructs with vasculature, skin appendages such as hair follicles, pigmentation, immune response, innervation, and hypodermis. Furthermore, we discuss the promising advances that iPSC technology offers in order to generate in vitro models of genetic skin diseases, such as epidermolysis bullosa and psoriasis. We also discuss how future integration of the next generation human skin constructs onto microfluidic platforms along with other tissues could revolutionize the early stages of drug development by creating reliable evaluation of patient-specific effects of pharmaceutical agents.Impact statementSkin is a complex tissue that hosts various specialized cell types and performs many roles including barrier, immune, and sensory functions. For human-relevant drug testing, there has been a growing interest in building more physiological skin constructs by incorporating different skin components, such as vasculature, appendages, pigment, innervation, and adipose tissue. This paper provides an overview of the strategies to build complex human skin constructs that can faithfully recapitulate human skin and thus can be used in drug development targeting skin diseases. In particular, we discuss recent developments and remaining challenges in incorporating various skin components, availability of iPSC-derived skin cell types and in vitro skin disease models. In addition, we provide insights on the future integration of these complex skin models with other organs on microfluidic platforms as well as potential readout technologies for high-throughput drug screening.
机译:许多疾病以及药物的副作用都通过皮肤症状表现出来。皮肤是一个复杂的组织,拥有各种专门的细胞类型,并发挥许多作用,包括物理屏障,免疫和感觉功能。因此,体外皮肤建模对组织工程提出了技术挑战。自1970年代首次尝试对人的表皮进行工程改造以来,人们越来越感兴趣的是通过掺入各种皮肤成分(例如用于色素沉着的脉管系统和黑素细胞)来生成模仿生理功能的全层皮肤构造。具有这些生理功能的人体皮肤模型中仿生药物的开发为药物发现,疾病建模,再生医学和皮肤生物学基础研究提供了新工具。然而,长期以来,由于不同细胞类型的有限可用性,建立共培养条件的挑战以及概括皮肤3D解剖结构的能力,这一目标已被长期拖延。诱导多能干细胞(iPSC)技术和微细加工技术(例如3D打印)的最新突破允许在用于药物筛选的体外皮肤模型中建立更可靠,更复杂的模型。在这篇综述中,我们着眼于当前的发展以及在产生具有脉管系统,皮肤附属物(例如毛囊,色素沉着,免疫反应,神经支配和皮下组织)的皮肤结构方面的挑战。此外,我们讨论了iPSC技术提供的有希望的进展,以便在遗传性皮肤病的体外模型中产生,例如大疱性表皮松解症和牛皮癣。我们还将讨论下一代人类皮肤构建物与其他组织一起在微流体平台上的整合如何通过对药物对患者的特异性作用进行可靠的评估来革新药物开发的早期阶段。专门的细胞类型,并发挥许多作用,包括屏障,免疫和感觉功能。对于与人类有关的药物测试,通过掺入不同的皮肤成分(例如脉管系统,附属物,色素,神经支配和脂肪组织)来构建更多生理皮肤构造的兴趣日益浓厚。本文概述了构建复杂的人类皮肤结构的策略,这些结构可以忠实地重塑人类皮肤,因此可以用于针对皮肤疾病的药物开发。特别是,我们讨论了结合各种皮肤成分,iPSC衍生的皮肤细胞类型的可用性以及体外皮肤疾病模型的最新发展和尚存的挑战。此外,我们提供了有关这些复杂的皮肤模型与微流控平台上其他器官未来整合的见解,以及用于高通量药物筛选的潜在读出技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号